文献速递淋巴瘤

循环肿瘤DNA在大B细胞淋巴瘤缓解评估中的应用

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-08-13

该研究整合五项前瞻性研究数据,对137例接受一线蒽环类化疗的大B细胞淋巴瘤患者连续监测409份血浆标本的循环肿瘤DNA作为微小残留病,发现治疗结束后可检测到ctDNA者2年无进展生存率显著低于不可检测者,且ctDNA的预后价值优于PET扫描的常规疗效标准。

要点

  • 治疗两个周期后55%患者ctDNA不可检测,治疗结束时78%患者不可检测。
  • 治疗结束时可检测ctDNA者2年PFS为29%,不可检测者为97%(HR 28.7)。
  • 治疗结束时ctDNA的预后价值优于PET扫描(可检测ctDNA HR 28.3 vs PET阳性HR 3.6)。

核心结论

  • 一线大B细胞淋巴瘤治疗后超敏ctDNA检测的预后价值优于常规影像学疗效标准。
  • 采用ctDNA-MRD细化缓解定义可能改善大B细胞淋巴瘤患者的临床和心理结局。

研究设计与样本

  • 整合五项前瞻性研究数据,纳入137例接受一线蒽环类化疗的大B细胞淋巴瘤患者。
  • 从治疗前标本中鉴定肿瘤特异性定相变异,并在标志性时间点监测。
  • 连续血浆标本盲法分析可检测ctDNA作为微小残留病。

主要发现

  • 随时间监测409份血浆标本,治疗两个周期后55%患者ctDNA不可检测,治疗结束时78%患者不可检测。
  • 中位随访37个月,治疗两个周期后可检测vs不可检测ctDNA者2年PFS为67% vs 96%(P=.0025;HR 6.9)。
  • 治疗结束时可检测vs不可检测ctDNA者2年PFS为29% vs 97%(P<.0001;HR 28.7)。
  • 治疗结束时ctDNA不可检测的92例(94%)患者无进展存活,可检测的19例(68%)患者进展或死亡。
  • 治疗结束时MRD状态预后价值优于PET扫描常规疗效标准(PET阳性HR 3.6,可检测ctDNA HR 28.3)。

关键数值与推荐

  • 治疗两个周期后ctDNA不可检测率55%,治疗结束时不可检测率78%。
  • 治疗两个周期后可检测vs不可检测ctDNA的2年PFS:67% vs 96%(P=.0025;HR 6.9)。
  • 治疗结束时可检测vs不可检测ctDNA的2年PFS:29% vs 97%(P<.0001;HR 28.7)。
  • 治疗结束时PET阳性HR 3.6,可检测ctDNA HR 28.3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the determination of remission. METHODS: We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL. Tumor-specific phased variants were identified from pretreatment samples and monitored at landmark time points. Serial plasma specimens were blindly analyzed for detectable ctDNA as MRD. MRD status was compared with conventional response criteria for prognosis of progression-free survival (PFS). RESULTS: We studied ctDNA-MRD in 137 patients by monitoring 409 plasma specimens over time. Detectable ctDNA rates decreased during therapy with 55% and 78% of patients achieving undetectable ctDNA after two cycles and at the end of therapy, respectively. After a median follow-up of 37 months, the 2-year PFS for patients with detectable versus undetectable ctDNA after two cycles was 67% versus 96% (P = .0025; hazard ratio [HR], 6.9) and after therapy was 29% versus 97% (P < .0001; HR, 28.7), respectively. Ninety-two (94%) patients with undetectable ctDNA at the end of therapy remained alive without progression, while 19 (68%) patients with detectable ctDNA progressed or died. MRD status at the end of therapy had greater prognostic utility than conventional lymphoma response criteria using positron emission tomography (PET) scans (HR, 3.6 for positive PET and 28.3 for detectable ctDNA). CONCLUSION: Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Roschewski M, Kurtz DM, Westin JR, et al. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 40802906. doi:10.1200/JCO-25-01534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。